Compare HSBC Holdings plc (HSBC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs TG Therapeutics Inc — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: HSBC Holdings plc is far larger — about 38.2× TG Therapeutics Inc's market cap, and HSBC Holdings plc pays a 4.05% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and TG Therapeutics Inc for 16 Days on average.
| HSBC | TGTX | |
|---|---|---|
Market Cap | $311.92B | $8.16B |
Volume | 3,546,658 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $107.86 | $59.06 |
52-Week Low | $65.67 | $26.94 |
Typical Hold Time | 36 Days | 16 Days |
Enterprise Value | $222.19B | $8.37B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.98, down 0.78% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and ROE of 12.44%. Recent earnings were mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. News highlights strategic moves like expanding in India equity broking and enhancing U.S. Premier services, while the CFO plans to step down in 2027.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include execution challenges from business restructuring and macroeconomic headwinds. Analysts are divided with 38.1% buy ratings, suggesting potential upside if earnings momentum improves, though bearish technicals warrant monitoring near support at $91.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
